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SUMMARY Psoriasis is a common disease in children and 
adolescents. Because of the chronic course of the disease, 
appropriate choice of therapy in particular stage of the disease, 
so-called rotation therapy, is of paramount importance. This article 
provides a review of therapeutic options for childhood psoriasis. 
Local therapy for psoriasis in children consists of corticosteroid 
preparations, calcipotriol, tars and dithranol, local retinoids, and 
local immunomodulators. Phototherapy (narrow band UVB, 
photochemotherapy PUVA baths) is now a part of psoriasis therapy 
in children. Systemic therapy retinoids (acitretin) methotrexate, 
cyclosporine is only used in severe forms of the disease such as 
erythrodermic, pustular and arthritic psoriasis. All these therapeutic 
options can be used as monotherapy or in various combinations.
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INTRODUCTION
 The treatment of childhood psoriasis requires 
serious and thorough consideration because of 
its chronic nature and importance of appropriate 
therapeutic approach in particular stages of the 
disease. Education of both psoriatic children and 
their parents is the first step in the treatment of 
childhood psoriasis (1). They should be properly 
explained the chronic nature of the disease and 
its tendency to exacerbations as well as sponta-
neous remission, especially in childhood (2). Pe-
diatric psoriatic patients and their parents should 
be warned of the factors provoking psoriasis and 
importance of their elimination. Environmental fac-
tors that cause psoriasis in children with genetic 
susceptibility to the development of psoriasis in-
clude skin infections and skin lesions. The most 
common provoking factors for childhood psoriasis 
are infections, primarily of upper respiratory tract, 
caused by hemolytic streptococcus (3). In such 
cases, it is necessary to treat the infection with an-
tibiotics, which is usually followed by improvement 
in the clinical picture of psoriasis. In some patients 
with guttate psoriasis (Fig. 1), prophylactic use of 
antibiotics or tonsillectomy is recommended (1). 
Koebner phenomenon, also known as isomorphic 
effect manifested by the appearance of psoriatic 
lesions at the site of mechanical skin trauma, sun-
burn, vaccination, etc., is rather common in child-
hood psoriasis. Therefore, these children and their 
parents should be explained the need of avoiding 
chronic skin irritation, recurrent skin lesions on 
physical activity, and wearing tight clothes. As 
psychical stress is an important factor in the de-
velopment of childhood psoriasis, the child should 
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be encouraged to communicate his/her troubles 
frankly and without fear, and to learn how to cope 
successfully with this chronic disease. Special at-
tention should be paid to adolescents who mostly 
suffer for their skin appearance (4).
LOCAL THERAPY FOR CHILDHOOD 
PSORIASIS
 Currently, local therapy for childhood psoriasis 
generally consists of local corticosteroids and cal-
cipotriol. Despite numerous side effects of local 
corticosteroids, they have found wide applica-
tion in all forms of psoriasis because of their rapid 
action, simple use, and availability. In children, the 
use of potent local corticosteroids is indicated for 
psoriatic plaques on the trunk and extremities with 
a pronounced inflammatory component. Therapy 
is administered twice daily for 14 days, to be con-
tinued with less potent corticosteroid preparations 
or neutral agents, depending on clinical picture. In 
case of a pronounced hyperkeratotic component, 
combined short-term application of a salicylic acid 
preparation is advised. Resistant plaques can be 
treated by short-term drug application under occlu-
sive dressing, thus greatly enhancing its efficacy 
but also the likelihood of side effects. Short-term 
(up to 7 days) use of nonfluoridated preparations 
is recommended for the cheeks, auricles, genitalia 
and flexural surfaces. Local corticosteroids have 
a prominent role in rotation therapy for psoriasis, 
therefore it is of utmost importance to use them 
under physician’s supervision to achieve highest 
therapeutic efficacy while avoiding numerous po-
tential side effects. It should be noted that various 
side effects of local corticosteroids such as skin 
atrophy, telangiectases, and especially striae may 
frequently occur at prepubertal and pubertal age 
after the use of very potent corticosteroid prepara-
tions (1,5) (Fig. 2).
 Calcipotriol, a synthetic vitamin D analog, is 
efficacious in the treatment of childhood psoriasis. 
It is advised to use it twice daily for 6 weeks, while 
initial results can be observed in 2 weeks. A num-
ber of clinical studies including a large number of 
children aged 2 years and older have demonstrat-
ed that calcipotriol is an efficacious and safe lo-
cal antipsoriatic from early childhood. It should be 
applied over not more than 30% of the total body 
surface. Unwanted reactions include possible ir-
ritation at the site of application (6,7).
 Use of calcipotriol in children needs further 
studies with respect to tolerability and long-term 
use.
 Tar and dithranol preparations can be used 
in older children. In our setting, these preparations 
are rarely used because patients tend to avoid 
them, since they may cause skin irritation, skin 
discoloration around the site of application, and 
underwear stain. Yet, these agents should not be 
forgotten when deciding on the most appropriate 
therapeutic option. It should be noted that dithra-
nol (0.3%-0.5%), carefully used as short contact 
therapy (20 to 60 minutes) upon involved skin ar-
eas under parental supervision, is highly efficient 
(8).
 Tazarotene, a local retinoid, is used in the 
form of 0.05% and 0.1% gel. As it frequently 
causes skin irritation, it is used in combination with 
local corticosteroids of moderate and high poten-
cy. Tazarotene and corticosteroid preparations are 
applied onto the psoriatic focus once daily each. 
As tazarotene may cause skin irritation even when 
applied in this combination, it is not frequently 
used in the treatment of childhood psoriasis (1,9).
Topical calcineurin inhibitors such as pimecroli-
mus and tacrolimus, recently successfully used 
in the management of atopic dermatitis, have 
proved efficacious in the treatment of facial and 
flexural psoriasis (10,11). However, there are no 
controlled clinical studies to demonstrate the ef-
ficacy of tacrolimus in the treatment of psoriasis 
in children.
 Neutral preparations may be used in mild 
forms of the disease because they are efficient in 
the reduction of scaling but cannot replace differ-
entiated therapy when inflammatory component 
is present. These preparations are also efficient 
in preventing the occurrence of new psoriatic le-
sions, especially in winter when the skin is drier.
 Phototherapy has become an integral and 
unavoidable modality of psoriasis treatment also 
in children. Phototherapy is indicated if psoriatic 
plaques involve more than 20% of the body area 
and fail to regress with local therapy. It should be 
noted that the use of phototherapy in children re-
quires close cooperation with parents and high 
competence of the dermatologist and other medi-
cal staff involved in therapy administration. The 
University Department of Dermatology and Ve-
nereology, Zagreb University Hospital Center in 
Zagreb has long-term experience in the use of 
phototherapy in children as young as 3 years of 
age. At our Department, only narrow band UVB 
(311±1 nm) is used in children. The advantages 
of narrow band UVB therapy over conventional 
UVB therapy in children are higher efficacy, lower 
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erythemogenic potential, prolonged periods of re-
mission, and safety. As we consider that determi-
nation of minimal erythemogenic dose is a time 
consuming and inappropriate test for children, we 
do not use it as a routine method. Since there is 
no standard protocol in the world literature for pho-
totherapy administration in children, we follow our 
own protocol tailored to each individual child's skin 
type and based on our own experience published 
in international periodicals (12,13).
 In pediatric patients, a combination of narrow 
band UVB phototherapy and local therapy (calci-
potriol, local corticosteroids, and less frequently 
dithranol) is used to increase therapeutic efficacy 
and to reduce the length of children's exposure to 
UV beams. Undesired side effects of photothera-
py are classified into short-term, which are usually 
mild and may include erythema, skin dryness with 
pruritus, and herpes virus activation; and long-
term, which include premature skin aging and 
photocarcinogenesis (12).
 The parents of children undergoing photo-
therapy should be explained that the dose of UVB 
irradiation received by phototherapy will cumu-
late with the radiation received on sun exposure. 
Photochemotherapy (PUVA) can be used excep-
tionally in severe cases of psoriasis in patients 
younger than 16 years involving more than 30% 
of body surface that fail to respond to the above 
therapeutic modalities. At our Department, only 
PUVA baths are used in the treatment of psoria-
sis in patients aged <18, because this therapy is 
associated with less side effects, shorter period 
of photosensitivity, and shorter time of exposure 
compared to oral PUVA. Only dermatologists with 
relevant experience in phototherapy may prevent 
acute and chronic side effects of PUVA therapy 
through careful patient selection and use of indi-
vidualized regimens. Children and adolescents re-
ceiving PUVA therapy require life-long monitoring 
(14).
 The beneficial effect of sunlight on the skin 
of patients with chronic psoriasis has long been 
known. Controlled sun exposure and stay at sea-
side during summer are recommended in the 
management of childhood psoriasis.
 SYSTEMIC THERAPY FOR CHILDHOOD 
PSORIASIS
 Systemic therapy is only used in severe forms 
of the disease such as erythrodermic, pustular and 
arthritic psoriasis where local therapy has proved 
inefficient (Figs. 3 and 4).
 Methotrexate is indicated in severe forms of 
generalized psoriasis that fail to regress to the 
above therapy, in exfoliative erythrodermic, pustu-
lar and arthritic psoriasis. Therapy with methotrex-
ate does not differ substantially between children 
and adults. Prior to therapy introduction, labora-
tory blood count tests and liver enzyme tests have 
to be obtained. The treatment begins with a test 
dose of 2.5 mg/week, which is then gradually in-
creased to the maximum of 7,5 mg/week, depend-
ing on body weight. Control laboratory blood count 
tests and liver enzyme tests are regularly ob-
tained, whereas liver biopsy is not needed in chil-
dren. The most common side effects associated 
with methotrexate therapy are nausea, headache 
and anorexia; however, the most serious compli-
cation is bone marrow suppression. The possible 
long-term oncogenic risk should be taken in con-
sideration in children administered methotrexate, 
although it has not yet been positively defined. 
The children who cannot take methotrexate per os 
can be administered it by intramuscular or intra-
venous route on a weekly basis. Remission of the 
disease is usually achieved within 3-6 weeks of 
therapy initiation. When remission has set in, the 
dose of methotrexate should be tapered (e.g., by 
2.5 mg/month) to the maintenance dose and then 
to therapy discontinuation (15,16).
 Oral retinoids are used in the treatment of se-
vere forms of pustular and erythrodermic psoriasis 
in children. In case of pustular psoriasis, therapy 
begins with acitretin in a dose of 0.75-1.00 mg/
kg body weight daily; in case of erythrodermic 
psoriasis, lower doses are used, 0.25-0.5 mg/kg 
body weight daily. The dose is gradually tapered, 
depending on therapeutic response and side ef-
fects. During treatment, control laboratory blood 
count, liver enzyme, cholesterol and triglyceride 
tests have to be regularly performed. Radiologic 
examinations should also be regularly performed 
for the potential toxic effects of retinoids on the 
skeletal system (premature epiphyseal fusion and 
hyperostosis). Contraception is warranted in pu-
bertal female patients because of the teratogenic 
effects of retinoids.
 Oral retinoids can be used in older children with 
severe, relapsing forms of generalized psoriasis 
in placibus, however, always in combination with 
other therapeutic options and over a short period 
of time (17, 18).
 Cyclosporine is used in the treatment of se-
vere forms of childhood psoriasis which fail to re-
gress to other therapies, exfoliative erythrodermic 
and pustular psoriasis. Therapeutic dose of cyclo-
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sporine is 2.5-5 mg/kg body weight daily for 3-4 
months, whereafter the dose is tapered to therapy 
discontinuation. During treatment, control labora-
tory blood count, liver enzyme, urea, creatinine 
tests and blood pressure measurements have to 
be regularly performed. The most common side 
effects include hypertension, renal toxicity and 
hepatotoxicity. On making therapy decision, the 
increased oncogenic risk in children administered 
cyclosporine should be taken in consideration 
(19,20).
CONCLUSION
 In the management of childhood psoriasis, the 
chronic nature of the disease should never be for-
gotten, necessitating caution on choosing therapy 
for every new exacerbation of the disease. Re-
sults obtained in population studies are used on 
patient counseling. According to literature, the risk 
of developing psoriasis is 4% if neither parent is 
affected, rising to 28% if one parent has psoriasis, 
and to 65% if both parents are affected (21). The 
need of close cooperation of parents and physi-
cians dermatologists in the diagnostic and thera-
peutic approach to childhood psoriasis cannot be 
overemphasized.
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